Mycophenolate Mofetil in the Therapy of Uveitic Macular Edema—Long-term Results

Abstract

Purpose: To assess the long-term efficacy of mycophenolate mofetil (MMF) in uveitic cystoid macular edema (CMO).

Methods: Thirty-eight uveitis patients with CMO treated with MMF with a follow-up of at least 5 years were analyzed. The patients were divided into two groups: group A, 24 patients with CMO that had occurred before initiation of MMF; group B, 14 patients who developed CMO for the first time during MMF.

Results: In group A, a complete remission of CMO without recurrences was observed in 12 of 24 patients (50%, rate: 0.12/patient-year). In group B, CMO occurred in 7 patients (50%) despite standard dosage of MMF, and in 7 patients (50%) during MMF dose reduction.

Conclusions: The results show that MMF is not always sufficiently effective as a long-term treatment for uveitic macular edema. Moreover, in some uveitis patients MMF cannot prevent new development of CMO.

Keywords::

• immunosuppressive treatment
• macular edema
• mycophenolate mofetil
• side effects
• uveitis

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.